États-Unis - anglais - NLM (National Library of Medicine)

rebel distributors corp - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. newborn infants display considerable variability in their tolerance to digoxin. premature and immature infants are particularly sensitive to the effec

États-Unis - anglais - NLM (National Library of Medicine)

bryant ranch prepack - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - digoxin tablets are indicated for the treatment of mild to moderate heart failure in adults. digoxin tablets increase left ventricular ejection fraction and improve heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin tablets should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin tablets increase myocardial contractility in pediatric patients with heart failure. digoxin tablets are indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin tablets are contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to other digitalis preparations usually

Namibie - anglais - Namibia Medicines Regulatory Council

pharmacare limited - digoxin - injection - digoxin injection 0.5mg/2ml

Israël - anglais - Ministry of Health

trima israel pharmaceutical products maabarot ltd - digoxin - tablets - digoxin 0.25 mg - digoxin - cardiac failure:digoxin kern pharma is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. the greatest therapeutic benefit is achieved in patients with ventricular dilatation.digoxin kern pharma is specifically indicated where cardiac failure is accompanied by atrial fibrilation.supraventricular arrhythmias:digoxin kern pharma is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.

Israël - anglais - Ministry of Health

teva pharmaceutical industries ltd, israel - digoxin - tablets - digoxin 0.25 mg - digoxin - digoxin - congestive heart failure (chf), atrial fibrillation, atrial flutter, supraventricular tachycardia.

États-Unis - anglais - NLM (National Library of Medicine)

atlantic biologicals corps - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula

Canada - anglais - Health Canada

pharmascience inc - digoxin - solution - 0.05mg - digoxin 0.05mg - cardiotonic agents

Canada - anglais - Health Canada

pharmascience inc - digoxin - tablet - 0.0625mg - digoxin 0.0625mg - cardiotonic agents

Canada - anglais - Health Canada

pharmascience inc - digoxin - tablet - 0.125mg - digoxin 0.125mg - cardiotonic agents

Canada - anglais - Health Canada

pharmascience inc - digoxin - tablet - 0.25mg - digoxin 0.25mg - cardiotonic agents